Prevail Therapeutics, an early stage biotech developing gene therapies for neurodegenerative diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The New York, NY-based company was founded in 2017 and plans to list on the Nasdaq under the symbol PRVL. Prevail Therapeutics filed confidentially on March 27, 2019. Morgan Stanley, BofA Merrill Lynch and Cowen are the joint bookrunners on the deal. No pricing terms were disclosed.
